EP-1092: Intensive radiotherapy in locally advanced head and neck squamous cell cancer- is it worth the pain?  by Pascoe, A. et al.
ESTRO 35 2016                                                                                                                                                    S525 
________________________________________________________________________________ 
patients were excluded because didn't receive CT (T1N0). 
From the remaining 100, 95 received concomitant plus 
adjuvant CT and 5 concurrent CT. We found a median OTT of 
49 days (range: 11-83 days). 39 patients completed CCRT in 
more than 7 weeks (50-83 days) from which 31 (79%) in 8 
weeks and the remaining 8 (21%) in more than 8 weeks. 
Interruption causes were by medical indication in 6 (15%), 
and non-clinical reasons in 33 (85% - patient no show, 
machine breakdown, and mis-coordination between 
departments). Compensations were performed at the 
discretion of the treating physician in the 8 patients with OTT 
longer than 8 weeks. No difference in local control (LC, p= 
0.766), overall survival (OS, p=0.855) or metastases free 
survival (p= 0.131). Cox regression confirmed age, N stage, 
local control and distant metastases status as prognostic 
factors however no impact was found for OTT (p = 0.890 for < 
7 weeks; p = 0.959 for < 8 weeks; and p = 0.960 for > 8 
weeks). 
 
 
Conclusion: In our study, we found no differences in LC and 
OS regardless OTT. These data must be interpreted with 
caution due to the high number of patients receiving CT that 
may compensate the unplanned interruptions in such a 
sensitive entity. Further studies with longer follow up are 
necessary to recommend or not withholding compensations in 
this setting. 
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Purpose or Objective: There have been numerous studies 
that have shown the importance of tumor volume as an 
independent prognostic factor over and above the T stage in 
head and neck cancer. However, data from the Indian 
subcontinent is sparse, even more so in patients treated by 
IMRT. This merits further study owing to possible differences 
in the biology of Indian head and neck cancer compared to its 
western counterpart. Ours was a prospective study that 
attempted to elucidate the role of tumor volume as a 
prognostic factor in locally advanced oropharyngeal and 
hypopharyngeal cancer. 
 
Material and Methods: We enrolled 87 patients of Stage III-IV 
squamous cell cancer of the hypopharynx(30), and 
oropharynx(57), who subsequently received definitive 
concurrent chemo radiation with IG-IMRT. The tumor volume 
was the gross tumor volume (TV) delineated on the planning 
CT scan and was calculated by the volume algorithm in the 
treatment planning system. The impact of TV on Locoregional 
relapse free survival (LRFS), Response to chemo radiation 
(RR), overall survival (OS),local control(LC) and regional 
control was assessed over a follow up of 2 years. The Shapiro 
wilk test was done for assessing normality. Survival analysis 
was by kaplan meir method with log rank testing for assessing 
significance between groups Univariate analysis was done by 
mann-whitney/chi square/fisher's exact test , multiariate 
analysis was done by logistic regression forward stepwise 
method and a model to predict LC was generated .An ROC 
curve analysis was done for estimation of cut offs.  
 
Results: The 2 year OS, LRFS, RR, LC& RC were 64%, 56%, 
65%,63% and 83% respectively .The T stage distribution was 
T2, T3&T4 (5/41/41).The TV was not normally distributed 
and the mean TV was 48 cc (5-167cc) with mean TV in T3 /T4 
patients of 39.9/60.9 cc. The mean TV in locally controlled 
patients was 35.4cc vs 70.8cc in uncontrolled patients .While 
the TV was a significant prognostic predictor for the OS , 
LRFS ,RR, and LC on univariate analysis , on the multivariate 
analysis only the TV predicted for LC. ROC curve analysis 
found cut off of 38 cc with 2 year LC of 84 % / 40% for 
TV<38cc / >38cc respectively with log rank p=0.001 with AUC 
of 0.759(0.653-0.865) and sensitivity/specificity of 82%/64%. 
ROC curve analysis of our oropharyngeal subgroup revealed 
similar results with a cut off of 38cc with AUC of 0.770 
(0.644-0.896) and sensitivity / specificity of 80%/66%.with 2 
year LC of 79%/30% for TV<38cc / >38cc (p=0.001). The 
likelihood of local failure increased by 3 % for 1cc increase in 
TV for the entire cohort & 3% for our oropharyngeal 
subgroup. 
 
 
 
Conclusion: TV is an independent prognostic factor in 
patients with head and neck cancer in predicting local 
control. Implications for existing management paradigms 
include, stratification according to TV in future randomized 
trials, consideration of altered fractionation and/or dose 
escalation to the primary disease for patients with TV>38cc.  
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Purpose or Objective: With increasing evidence for 
combined modality treatment in locally advanced squamous 
cell cancer of the head and neck (HNSCC), there remains 
debate about the best treatment approach for patients with 
T4 disease. Local control in HNSCC is extremely important 
due to the morbidity and mortality associated with local 
recurrence. However treatment itself can be associated with 
significant morbidity. The purpose of this review is to 
determine both overall survival (OS) and local control rates 
for patients with T4 tumours treated with Intensity 
Modulated Radiotherapy (IMRT) with or without prior surgery. 
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Material and Methods: Retrospective review of all patients 
with T4 HNSCC treated with IMRT at our centre, between 
December 2010 and February 2013. Overall, relapse free and 
local relapse-free survival were calculated from date of 
biopsy to date of death, relapse or last follow up. 
 
Results: Of the 69 patients with T4 tumours, 73.9% were 
male and median age was 69 (41-84). 50.7% were 
oropharyngeal tumours and 73.9% were node positive. 
Primary resection was performed in 18 patients. Eighteen 
patients underwent radiotherapy alone and 51 received 
concurrent chemotherapy (45 cisplatin, 6 cetuximab). Median 
follow up was 3.0 years (range = 3 months to 3.9 years). 28 
patients died; 22 related to HNSCC, 6 from other causes. 
Overall survival at 3 years was 58.0% (95% CI: 44.6 to 69.1). 
28 patients (40.6%), relapsed with median time to relapse of 
8 months. 20 patients (29.0%) relapsed locoregionally and 11 
patients (15.9%) developed distant metastatic disease. For 8 
patients, distant metastases were the only site of relapse. 
Surgical salvage was performed in 6 patients with 
locoregional relapse only, 2 of whom have since died from 
causes related to HNSCC. Relapse free survival at 3 years was 
54.0% (95% CI: 40.5 to 65.8) and loco-regional relapse free 
survival at 3 years was 65.5% (95% CI: 51.2 to 76.5). Nineteen 
patients (27.5%) had residual disease on PET scan 12 weeks 
post treatment. These patients were at greater risk of 
relapse and death with 3 year overall survival of 37.0% (95% 
CI 15.4 to 59.0) and 3 year relapse free survival of 40.5% 
compared to 3 year overall survival of 85.7% (53.9 to 96.2) 
and 3 year relapse free survival of 79.0% (47.9 to 92.7) in 
patients with normal PET scans.  
 
Conclusion: There is a significant risk of relapse and death in 
T4 HNSCC tumours, particularly in those with residual disease 
following radiotherapy. However, IMRT, either alone or in 
combination with chemotherapy or surgery, achieved 3 year 
locoregional control of 65.5% (95% CI 51.2%-76.5%). This is a 
meaningful local control rate for locally advanced disease in 
which local relapse confers significant morbidity. 
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Purpose or Objective: To investigate the role of HPV status, 
comorbidity and polypharmacy on outcomes of elderly 
patient with oropharyngeal carcinoma (OPC). 
 
Material and Methods: We retrospectively reviewed a 
prospectively compiled cohort of elderly patients (>70 years) 
with newly diagnosed OPC treated with curative radiotherapy 
(RT)+/- systemic therapy in 2000-2013. Tumor HPV status was 
assessed by p16 staining. Comorbidities were quantified by 
Charlson Comorbidity Index (CCI). The Comorbidity-
Polypharmacy Score (CPS), a validated predictor of outcome 
for older trauma patients, was used to take into account the 
number of medications as a surrogate of the severity of 
comorbidities. Overall survival (OS), and relapse-free survival 
(RFS) were calculated and compared between HPV-positive 
[HPV(+)] and HPV-negative [HPV(-)] cohort. Two multivariate 
analysis (MVA) models [one included CCI (MVA-CCI), one 
included CPS (MVA-CPS)] were used to confirm the prognostic 
value of HPV, CCI or CPS, pack-year (PY) smoking, ECOG 
performance status (PS), and age for OS adjusted for disease 
extent (T, N). 
 
Results: Tumor HPV status was ascertained in 229 of 287 
(80%) patients revealing 115 HPV(+) and 114 HPV(-). Median 
age was 74.8 years (range 70-93). Systemic agents were given 
in 48 (21%) patients [chemo 17; EGFR inhibitor 31). RT 
incompletion [5 (4%) vs 8 (7%), p=0.41) and unplanned RT 
break rates [22 (19%) vs 28 (25%), p=0.34] were similar 
between HPV(+) vs HPV(-) cohorts. No significant difference 
in distribution of CCI (p=0.30) or CPS score (p=0.22) between 
HPV(+) vs HPV(-) cases. CCI and CPS have a moderate 
correlation (Kappa: 0.51). Median follow-up was 4.6 years. 
HPV(+) patients had better 5-year OS (59% vs 32%, p<0.001) 
and RFS (75% vs 54%, p<0.001) compared to HPV(-). MVA 
adjusted for T and N-category confirmed HPV(+) status was 
the strongest prognostic factor (PF) for OS [MVA-CCI: HR 0.52 
(95% CI 0.34-0.79), p=0.002; MVA-CPS: HR 0.56 (0.36-0.85), 
p=0.007]. CPS was also a PF for OS [HR 1.05 (1.00-1.11), 
p=0.044]. CCI was not significant (p=0.17). ECOG PS was also 
a PF [MVA-CCI: HR 2.31; MVA-CPS: HR 2.32, both p<0.001]. 
Smoking (>20 PY) was prognostic in MVA-CCI (HR 1.62, 
p=0.035) and marginally prognostic in MVA-CPS (HR 1.56, 
p=0.056). Age was not significant in MVA-CCI (p=0.16) or 
MVA-CPS (p=0.65) models. 
 
Conclusion: In elderly patients with OPC, HPV status is a 
strong PF for OS. Neither chronologic age nor CCI is 
prognostic. Higher CPS is correlated with poorer OS, which 
implies that inclusion of polypharmacy in addition to 
comorbidity might be a better reflection of competing 
mortality risk in this population, and attention to competing 
mortality causes may influence outcome for this complex 
patient group. Further validation of prognostication of CPS in 
elderly OPC population is warranted. 
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Purpose or Objective: While the total tumor volume(TTV) 
has been extensively analyzed in literature as a prognostic 
factor in head and neck cancer, there exist no studies to date 
that have analysed the impact of TTV on response to chemo 
radiation(CCRT), particularly from the Indian subcontinent 
and in patients treated with IMRT. We did a prospective study 
that attempted to elucidate the role of total tumor volume 
as a prognostic factor in locally advanced oropharyngeal and 
hypopharyngeal cancer. 
 
Material and Methods: We enrolled 87 patients of Stage III-IV 
cancer of the oropharynx(57),and hypopharynx(30) , who 
received definitive CCRT with IMRT. The TTV was the sum of 
the gross tumour volume and the nodal volume delineated on 
the planning CT scan. The impact of TTV on Locoregional 
relapse free survival (LRFS), response to chemoradiation (RR) 
and overall survival (OS) was assessed over a follow up of 2 
years. Survival analysis was by kaplan meir method with log 
rank testing for assessing significance between groups 
Univariate analysis was by mann-whitney/chi square test 
,multivariate analysis was by logistic regression forward 
stepwise method and a model to predict response was 
generated .ROC curve analysis was done for calculating cut 
offs. A classification tree for Response was generated using 
CART analysis (CHAID method). 
 
Results: The 2 year OS, LRFS, and RR were 64%, 56% & 65%. 
The T stage distribution was T2(5) , T3(42) ,T4(42) & N stage 
was N0 (11),N1(28),N2A(10),N2B (17),N2C(17) & N3(4).The 
mean TTV was 67.4 cc (8-191 )cc. The mean TTV in 
Responders/ non responders was 51.9 cc / 95.5cc.On 
multivariate analysis, the TTV was a significant prognostic 
factor for RR & LRFS but not for OS. ROC curve analysis found 
cut off of 48 cc for RR with AUC of 0.778(0.672-0.884) ans 
sensitivity/specificity of 87% /60%.The RR for the <48cc and 
